Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Trial Profile

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Ciclosporin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Mycophenolate mofetil (Primary) ; Mycophenolate mofetil (Primary) ; Antithymocyte globulin
  • Indications Acute myeloid leukaemia; Advanced breast cancer; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jul 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
    • 05 Jul 2018 Planned primary completion date changed from 15 Jun 2018 to 15 Jun 2019.
    • 23 Oct 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top